Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ALXR/FPR Mediated Signaling in Severe Asthma (AMSA)-The Severe Asthma Research Program (SARP) III

NCT01761630 is registered in ClinicalTrials.gov with Elliot Israel, MD as lead sponsor.

NCT NCT01761630
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01761630 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ALXR/FPR Mediated Signaling in Severe Asthma (AMSA)-The Severe Asthma Research Program (SARP) III
Lead sponsor
Elliot Israel, MD
Phase
Observational
Overall status
Completed
Start date
December 31, 2012
Completion date
January 15, 2021
Enrollment
126 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

asthma